The lung cancer burden in Asian regions is expected to double or more between 2020 and 2050, underscoring a pressing need for comprehensive preventive measures & healthcare interventions.
In recent years, precision oncology has transformed the diagnosis and treatment of advanced-stage non-small cell lung cancers (NSCLC). Targeted treatments have become increasingly available as oncogenic drivers are identified. Targeted therapy and molecular testing are now recognized as the future in lung cancer treatment. Most of these innovative medications have been shown to be both clinically effective and safe.
Download this insightful release to understand how Johnson&Johnson uncover three key themes in this White paper:
Disease burden in NSCLC
Economic burden in NSCLC
Call to action.
Please note: Clarivate is a research partner to Johnson&Johnson on this white paper and other critical projects.